Corona S P, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D
Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
Med Oncol. 2017 Jul;34(7):119. doi: 10.1007/s12032-017-0975-5. Epub 2017 May 19.
Breast cancer (BC) is the most common cancer in women worldwide. One in eight women will develop the disease in her lifetime. Notwithstanding the incredible progress made in this field, BC still represents the second most common cause of cancer-related death in women. Targeted drugs have revolutionised breast cancer treatment and improved the prognosis as well as the life expectancy of millions of women. However, the phenomenon of primary and secondary pharmacological resistance is becoming increasingly evident, limiting the efficacy of these agents and calling for a better in-depth knowledge and understanding of the biology as well as the biochemical crosstalk underlying the disease. The advent of laboratory technologies in the clinical setting such as the routine use of next generation sequencing has allowed identification of new genetic alterations as well as providing a precise picture of the molecular landscapes of each tumour. Consequently, new specific therapeutic approaches are becoming available to minimise or delay the occurrence of resistance. In this review, we analyse the latest research and news from the clinical development side for each BC subtype.
乳腺癌（BC）是全球女性中最常见的癌症。每八位女性中就有一位在其一生中会患上这种疾病。尽管该领域取得了令人难以置信的进展，但乳腺癌仍是女性癌症相关死亡的第二大常见原因。靶向药物彻底改变了乳腺癌的治疗方式，改善了数百万女性的预后和预期寿命。然而，原发性和继发性耐药现象日益明显，限制了这些药物的疗效，因此需要更好地深入了解该疾病的生物学特性以及潜在的生化相互作用。临床环境中实验室技术的出现，如下一代测序的常规使用，使得能够识别新的基因改变，并提供每个肿瘤分子图谱的精确图像。因此，新的特异性治疗方法正在出现，以尽量减少或延迟耐药的发生。在本综述中，我们分析了每种BC亚型临床开发方面的最新研究和进展。
